Trial Profile
An Open-label, Long Term, Multi-center Study to Assess the Safety and Efficacy of Fixed Dose Combinations of Solifenacin Succinate (6 gm and 9 mg) With Tamsulosin Hydrochloride OCAS 0.4 mg, in Male Subjects With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) With a Substantial Storage Component
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Solifenacin/tamsulosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Neptune II
- Sponsors Astellas Pharma
- 21 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 15 Apr 2014 Results presented at the 29th Congress of the European Association of Urology.
- 29 Aug 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004068).